December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ:ANGO)

12.93 +0.53 (+4.23%)
Streaming Delayed Price Updated: 1:52 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AngioDynamics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
AngioDynamics to Participate in the UBS Global Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Host Virtual Cardiovascular Investor Event
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Participate in Upcoming Investor Conferences
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
From AngioDynamics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.